CORTICOSTEROIDS

New concerns will raise questions about when it’s appropriate to use SHORT courses of oral corticosteroids in adults.

We know long-term steroid use can lead to adverse effects, such as osteoporosis and weight gain. And using a steroid for just a few days can cause hyperglycemia, insomnia, etc.

Now evidence links steroid use for just one week to a slightly higher 3-month risk of fractures, venous thromboembolism, and sepsis. But these findings may be due to other factors, such as the patient’s underlying condition.

Use this as an opportunity to re-evaluate short-term oral steroids.

For example, discourage using short-course steroids for acute sinusitis, bronchitis, or sore throat. In most cases, steroids reduce symptoms by one day at most...and potential risks may outweigh benefits.

But recommend 5 days of a steroid for an asthma or COPD exacerbation...or for an acute gout flare as an alternative to NSAIDs.

Prescribers often reach for a methylprednisolone dose pack (Medrol, etc) if a short-course steroid is needed. But point out that once-daily prednisone works just as well...is simpler...and costs less.

Explain tapering usually isn’t needed for short-course steroids.

Listen to PL Voices to hear our experts discuss the risks and benefits of short courses of steroids. And use our Risks With Short-Course Steroids commentary for appropriate indications and regimens.

(For more on this topic, see Clinical Resource #330706 at PharmacistsLetter.com.)

Overview of current therapy

1. What is known about the risks of systemic corticosteroid use? What is the evidence to support the efficacy of short courses of corticosteroids for common uses?

Analysis of new study

2. What type of study was this? How were the patients selected for inclusion?

3. How were the patient groups and outcomes defined?

4. What were the results of the study?

5. What were the strengths and weaknesses of this study?
6. Were the results expressed in terms we care about and can use?

How should the new findings change current therapy?

7. Do the results change your practice? How?

Apply the new findings to the following case

J.W. is a 67-year-old male with a past medical history significant for COPD (he is a former smoker) and low back pain due to lumbar degenerative disc disease. His home medications include tiotropium 18mcg 2 puffs inhaled daily, albuterol inhaled every 6 hours as needed, and acetaminophen OTC as needed for back pain.

He’s coming in today for an urgent care appointment, complaining of a sore throat and runny nose for the past 3 days after watching his 4-year-old granddaughter who was diagnosed with RSV last week and unable to attend daycare. J.W. denies any shortness of breath or wheezing currently, but feels tired and achy with a slight dry cough. He’s been compliant with his medications, although the inhalers are very expensive and hard for him to afford. So far, he hasn’t required additional albuterol treatments while he’s been sick. On exam he is afebrile, with a BP of 123/82 and heart rate of 82. His oxygen saturation is 94% and respiratory rate is 18. His oropharynx is mildly erythematous and he has swollen nasal turbinates. Otherwise his exam is normal, including his lungs being clear with no wheezing or rales.

8. What should you suggest to manage J.W.’s symptoms?

You educate J.W. on viral illnesses and recommend he try acetaminophen for myalgias and sore throat. You encourage him to stay well hydrated and to try an OTC decongestant plus a first-generation antihistamine for cough if he feels he needs it.

J.W. reports getting prednisone last year when this happened, and he wants to know whether this might help him again.
9. What can you discuss with J.W. about the benefits and risks of a short corticosteroid course?

J.W. appreciates your explanation and agrees to try conservative therapy. Based on his history of COPD, you ask him to follow up in a week to see how he’s doing.

On his return visit, he reports his throat is no longer sore but that he is unable to sleep at night because of coughing with green sputum production. He is also using his albuterol inhaler 3-4 times every day and feels short of breath with minimal activities at home. His exam is significant for oxygen saturation of 92% with diffuse wheezing in all lung fields. No rales are appreciated. He is coughing throughout your visit.

10. What are options for managing J.W.’s COPD exacerbation?

You start J.W. on prednisone 40 mg daily and doxycycline 100 mg BID for the next 5 days. Two days later you call and find out he’s feeling somewhat better and has only used his albuterol inhaler 2 times since starting his medication. He thanks you and asks if there is anything he can do to prevent this in the future.

11. What measures should you consider to lower J.W.’s risk of a future COPD exacerbation?
References


Additional Pharmacist’s Letter Resources available at PharmacistsLetter.com


PL Journal Club builds on Pharmacist’s Letter to provide you with background for your own journal club discussions. We’ll won’t bring up every possible question, but you can…in your own group meetings. If a question comes up, go to PharmacistsLetter.com to find more background. As a PL Journal Club participant, you get access to all of Pharmacist’s Letter. Feel free to call or email us with suggestions or if we can be of assistance… 209-472-2240 or PLJournalClub@plerter.com.

Instructions
Go to PharmacistsLetter.com to get the PL Journal Club PARTICIPANT NOTES. Use the search function to look for “Journal Club.” You’ll also get great background materials, including Pharmacist’s Letter and clinical resources. PL Journal Club functions like a typical group meeting, except that it is organized for you with the expert analysis of important new studies done by the large Pharmacist’s Letter research and editorial staff. Let the questions serve as a springboard for your discussions. Use our patient cases or your own cases to shape the discussion. Each month, PL Journal Club reviews a topic that is also covered in Pharmacist’s Letter. You’ll also find a library of previous PL Journal Clubs online for your use.

PL Journal Club Contributing Editors:
Lori Dickerson, PharmD, FCCP, Editor; Jennifer Nieman, PharmD, BCPS, Assistant Editor; Lisa D. Mims, MD, Department of Family Medicine, Medical Univ of South Carolina, Charleston, SC; Maribeth Porter, MD, Department of Community Health and Family Medicine, Univ of Florida, Gainesville, FL.

Editors and Authors: Jeff Jellin, PharmD, Editor-in-Chief; Sherri Boehringer, PharmD, BCPS, Senior Editor, VP Content; Karen Davidson, PharmD, Senior Editor; Tammy Armeni, RPh, PharmD, Editor, Director of Continuing Education; Melissa Blair, PharmD, FASHP, FCCP, BCPS; Sandye Chabot, PharmD; Lori Dickerson, PharmD, FCCP; Rachel Maynard, PharmD; Kimberly Palacios, PharmD, Editors; Stacy Hester, RPh, BCPS, Crystal Maric, Bsc Pharm, MBA, ACPR, Associate Editors; Bethany Bryant, PharmD, BCPS; Vickie Danaher, PharmD; Leslie Gingo, PharmD, BCPS; Flora Harp, PharmD; Tanner Higginbotham, PharmD; Jennifer Nieman, PharmD, BCPS; Brea Rowan, PharmD, BCPS; James Van, BSc; Pharm; Don Weinberger, PharmD; Marlea Wellein, PharmD, BCPS, Assistant Editors; Karen Wilson, BA, Manuscript Editor; Minda Paglinawan, BA, Assistant Manuscript Editor; Jenni Mangrum, BS, CPhT; Assistant Education and Accreditation Editor; Mark Graber, MD, MSHCE, FACEP, Associate Clinical Editor. Contributors: Jill Allen, PharmD, BCPS; Melanie Cupp, PharmD, BCPS; Katie Lucaria, BSc Pharm, ACPR; Heidi Liston, BSc Pharm, PharmD; Lu-Anh Murdock, BSc Pharm; Annette Murray, BSc Pharm; Neeta O’Mara, PharmD, BCPS; Jennifer Pennington, RN, BSN. Editorial Advisors: Christophe Anslinger, PA-C; Thomas Barringer, MD, FAHA, FNLA; Christopher Barry, PA-C, MMSc; William Bednar, MD, FAHA; Dawn Brodie, PharmD; Robert Brownie, MD, FACP; Stephen Brunton, MD; Holley Bush, PharmD; Peter Carek, MD, MS; Gary Choy, PharmD; Matthew Cline, MD; John Connolly, MD, FACP, FCCP; Sandra Counts, PharmD; Hikmat Fikrat, PhD; Rex Force, PharmD, FCCP, BCPS; Lawrence Frank, MD, FACP; Peter Garbeff, MD; Mark Garofoli, PharmD, MBA, CGP; Denise Gontiz, FNP-C; Charles Green, RPh; Susan Halasi, MSc Pharm; John Hambright, PharmD; Roland Hart, MD; Kyle Herbold, MD; Patricia Hatton, MD; Sydney Hendry, MD, FAHA, FNLA; Raissa Hill, DO; Jerry Jones, MD; Sheila Kapre, MD, FACP, FCCP; Adam Kaye, PharmD, FASCP, FCPhA; William Kehoe, PharmD, MA, FACC, BCPS; Joshua Lenchus, DO, RPh, FACP, SFHM; Stanley Leong, PharmD; Kevin Maeda, PharmD; Christine Marsh, RPh, Eric Matheson, MD, MS; Christina McLaughlin, CPhT, EMT; Kay Niegel, RPh; Mike Pastrick, RPh, BCACP; Barbara Rankin, MD; Jenna Reel, PharmD, BCPS, CPP, CDE; George Rushwaar, MD; Sandy Robertson, PharmD; Edward Rogan, PharmD; BCACP; Gerald Rubley, MSN, PharmD; Ruth Ruffe, PharmD; AnnieMarie Santos, MD; David Schneider, MD; Allen Shaughnessy, PharmD, MMEdEd; Jonathan Szkotak, PharmD, BCACP; Joshua Tessier, DO; Bruce Uch, PharmD; John David Williamson, MD, FAAA, Raymond Wong, MD; William Yee, PharmD, FASHP, FCSHP; Kent Yep, RPh.

Advisory Board: Evan Ballard, MD, Jonesville Family Medical Ctr; Melvin Baron, PharmD, MPA, Univ of Southern Calif; Jan Basile, MD, FACP, Medical Univ of South Carolina; Robert Bickerton, MD, FACCP; Reid Blackwelder, MD, FACP, EA Tennessee State Univ; Kevin Brown, MD, FACOG, Texas A&M; R. Keith Campbell, RPh, FAADE, FASHP, FAPhA, CDCE, Washington State Univ; Andrea Darby-Stewart, MD, M HonorHealth; Anthony A. Donato, Jr., MD, MHPE, Reading Health System; Jan Drutz, MD, Baylor College of Med; Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CFP, FSAAN, DCC, Fitzgerald Health Ed Associates; Barry Gidal, PharmD, BCACP, UC San Francisco; Stuart Haines, PharmD, BCPS, BCACP, BC-ADM, FCCP, FASHP, FAPhA, Univ of Miss;Jefferson Harmon, Jr, MD, Col, USAF, MC, FS; B. Mark Hess, MD, FACP; John Holman, MD, MPH, FAAA; Eric Jackson, PharmD, FCCP, BCPS, Univ of Conn; Peter Jacobsen, PhD, DDS, Univ of the Pacific; Paul Jensen, MD, PharmD, FAAA; Alan David Kaye, MD, PhD, DABA, DABPM, DABIPP, Louisiana State Univ; Steve Kayserr, PharmD, UC San Francisco; Brian Kessler, DO, FACOFP, Lincoln-Memorial Univ; Edgar Lerma, MD, FACP, FASN, FAHA, Univ of Illinois at Chicago; Evan L. Lipiccs, MD; Mark McComb, MD, Oscar G. Johnson VA Medical Ctr; Stephen L. McKernan, BSc Pharm, ND, DO, FAAA; Sam Houston State Univ; Steven E. Nissen, MD, MACC, Cleveland Clinic; Brenden O’Hara, RPh, BCACP, Blue Cross/Blue Shield of NC; Douglas S. Pauw, MD, MACP, Univ of Washington; Dan Perri, BSc Pharm, MD, FRCPC, McMaster Univ; Charles Ponte, BS, PharmD, FAAE, FAPhA, FASHP, FCCP, FNAAP, West Virginia Schools of Pharmacy & Medicine; Joseph E. Scherger, MD, MPH, Eisenhower Medical Ctr; Arthur Shinn, PharmD, FASCP, Managed Pharmacy Consultants; Kelly Anne Spratt, DO, FACCP, Univ of Pennsylvania; Dan Steiber, RPh, Genesis Pharmacy Consultants; Tom Vickery, PharmD, OPTION Care; C. Wayne Weart, PharmD, FAPhA, BCPS, Medical Univ of South Carolina; Craig D. Williams, PharmD, FNLAs, BCPS, Oregon Health & Science Univ.

DISCLOSURE:
The editors of this activity and its publisher, Therapeutic Research Center, have no relevant financial interests related to the products or services covered by this activity. Therapeutic Research Center/Pharmacist’s Letter does not receive any commercial support and does not accept any advertising. It is completely independent and is supported entirely by subscriptions. Pharmacist’s Letter focuses on delivering completely objective, unbiased drug information and advice for the benefit of subscribers.

Unbiased Evidence and Recommendations for the Pharmacist on New Developments in Drug Therapy
3120 West March Lane, Stockton, CA 95219
TEL (209) 472-2240 – FAX (209) 472-2249
PharmacistsLetter.com
The contents are copyrighted. © 2017 Therapeutic Research Center. All Rights Reserved.